This study looks at the long-term safety and effectiveness of pembrolizumab, a medicine for advanced tumors. The study involves people who were part of earlier pembrolizumab studies. Pembrolizumab is a type of cancer treatment known as immunotherapy, which helps the body's immune system fight cancer.
Participants will join one of three phases based on their previous study phase:
- First Course Phase: Up to 35 doses every 3 weeks or 17 doses every 6 weeks of pembrolizumab.
- Survival Follow-up Phase: Monitors participants post-treatment.
- Second Course Phase: Up to 17 doses every 3 weeks or 8 doses every 6 weeks if needed.
Participants must meet specific health criteria to join. There's no exclusion, but for Second Course Phase, severe allergies to pembrolizumab, recent live vaccines, or certain health conditions might prevent participation.
- Study Length: About 2 years, with dosing every 3 or 6 weeks.
- Requirements: Must have been in a previous pembrolizumab study.
- Risks: Possible side effects from pembrolizumab and lenvatinib.
How understandable was the trial content above?
Hard to understand
Easy to understand